WO2024133845

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to advancing the next generation of oncology therapies for patients with difficult-to-treat cancers. The company's lead program, AVZO-021, is a potentially best-in-class, highly selective Cyclin-dependent kinase 2 (CDK2) inhibitor currently in Phase 1 development for advanced solid tumors. Avenzo's strategy focuses on acquiring and developing high-potential assets that address mechanisms of resistance to current therapies, including a pipeline that features antibody-drug conjugates and small molecule inhibitors. Founded by the leadership team behind Turning Point Therapeutics, the company leverages deep expertise in precision oncology to accelerate drug development. Avenzo is backed by a strong syndicate of life science investors and is headquartered in San Diego, California.